Simcere Pharmaceutical Group Limited (2096.HK)
HKD 8.99
(2.63%)
HKD 8.99
(2.63%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.42 Billion CNY | -5.14% |
| 2022 | 1.5 Billion CNY | -7.89% |
| 2021 | 1.63 Billion CNY | -50.43% |
| 2020 | 3.3 Billion CNY | 12.21% |
| 2019 | 2.94 Billion CNY | 26.88% |
| 2018 | 2.31 Billion CNY | 75.91% |
| 2017 | 1.31 Billion CNY | 0.0% |
| 2012 | - CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1 Billion CNY | -29.82% |
| 2024 Q2 | 1 Billion CNY | 17.83% |
| 2023 Q3 | 1.34 Billion CNY | 16.69% |
| 2023 Q4 | 1.42 Billion CNY | 5.92% |
| 2023 FY | 1.42 Billion CNY | -5.14% |
| 2023 Q1 | 1.07 Billion CNY | -28.44% |
| 2023 Q2 | 1.15 Billion CNY | 7.25% |
| 2022 FY | 1.5 Billion CNY | -7.89% |
| 2022 Q4 | 1.5 Billion CNY | 4.06% |
| 2022 Q3 | 1.44 Billion CNY | -4.39% |
| 2022 Q2 | 1.51 Billion CNY | 3.5% |
| 2022 Q1 | 1.46 Billion CNY | -10.56% |
| 2021 Q3 | 1.6 Billion CNY | -24.44% |
| 2021 Q2 | 2.12 Billion CNY | 1.81% |
| 2021 Q1 | 2.08 Billion CNY | -36.8% |
| 2021 FY | 1.63 Billion CNY | -50.43% |
| 2021 Q4 | 1.63 Billion CNY | 1.97% |
| 2020 Q4 | 3.3 Billion CNY | 1.17% |
| 2020 Q2 | 3.73 Billion CNY | 1.03% |
| 2020 Q1 | 3.69 Billion CNY | 25.81% |
| 2020 FY | 3.3 Billion CNY | 12.21% |
| 2020 Q3 | 3.26 Billion CNY | -12.73% |
| 2019 Q4 | 2.94 Billion CNY | 0.9% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 FY | 2.94 Billion CNY | 26.88% |
| 2019 Q3 | 2.91 Billion CNY | 0.0% |
| 2018 FY | 2.31 Billion CNY | 75.91% |
| 2017 FY | 1.31 Billion CNY | 0.0% |
| 2013 Q1 | 737.77 Million CNY | 0.0% |
| 2013 Q3 | 906.96 Million CNY | 21.86% |
| 2013 Q2 | 744.29 Million CNY | 0.88% |
| 2012 Q4 | - CNY | 0.0% |
| 2012 FY | - CNY | 0.0% |
| 2012 Q1 | - CNY | 0.0% |
| 2012 Q2 | - CNY | 0.0% |
| 2012 Q3 | - CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 52.86 Million HKD | -2603.433% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.93 Billion HKD | 75.903% |